nodes	percent_of_prediction	percent_of_DWPC	metapath
Vidarabine—Cytarabine—Gemcitabine—breast cancer	0.201	0.35	CrCrCtD
Vidarabine—Azacitidine—Gemcitabine—breast cancer	0.19	0.333	CrCrCtD
Vidarabine—Decitabine—Gemcitabine—breast cancer	0.181	0.317	CrCrCtD
Vidarabine—ADK—mammary gland—breast cancer	0.00402	0.0682	CbGeAlD
Vidarabine—ADK—nipple—breast cancer	0.00333	0.0564	CbGeAlD
Vidarabine—DPP4—embryo—breast cancer	0.00266	0.0451	CbGeAlD
Vidarabine—ADA—adipose tissue—breast cancer	0.00221	0.0376	CbGeAlD
Vidarabine—DPP4—epithelium—breast cancer	0.00217	0.0368	CbGeAlD
Vidarabine—ADK—skin of body—breast cancer	0.00213	0.0361	CbGeAlD
Vidarabine—ADA—female reproductive system—breast cancer	0.00204	0.0345	CbGeAlD
Vidarabine—ADK—endometrium—breast cancer	0.00201	0.034	CbGeAlD
Vidarabine—ADA—adrenal gland—breast cancer	0.00199	0.0337	CbGeAlD
Vidarabine—DPP4—endometrium—breast cancer	0.00195	0.033	CbGeAlD
Vidarabine—ADA—bone marrow—breast cancer	0.00192	0.0326	CbGeAlD
Vidarabine—ADORA2A—female reproductive system—breast cancer	0.00185	0.0314	CbGeAlD
Vidarabine—ADK—pituitary gland—breast cancer	0.00182	0.0308	CbGeAlD
Vidarabine—ADK—adipose tissue—breast cancer	0.00181	0.0307	CbGeAlD
Vidarabine—ADORA2A—adrenal gland—breast cancer	0.00181	0.0306	CbGeAlD
Vidarabine—DPP4—uterus—breast cancer	0.00179	0.0304	CbGeAlD
Vidarabine—DPP4—adipose tissue—breast cancer	0.00175	0.0298	CbGeAlD
Vidarabine—ADA—endocrine gland—breast cancer	0.00172	0.0292	CbGeAlD
Vidarabine—ADK—female reproductive system—breast cancer	0.00166	0.0282	CbGeAlD
Vidarabine—ADK—adrenal gland—breast cancer	0.00162	0.0275	CbGeAlD
Vidarabine—DPP4—female reproductive system—breast cancer	0.00161	0.0273	CbGeAlD
Vidarabine—DPP4—adrenal gland—breast cancer	0.00157	0.0267	CbGeAlD
Vidarabine—ADK—bone marrow—breast cancer	0.00157	0.0266	CbGeAlD
Vidarabine—ADORA2A—endocrine gland—breast cancer	0.00157	0.0266	CbGeAlD
Vidarabine—DPP4—bone marrow—breast cancer	0.00152	0.0258	CbGeAlD
Vidarabine—ADK—female gonad—breast cancer	0.00151	0.0257	CbGeAlD
Vidarabine—DPP4—female gonad—breast cancer	0.00147	0.0249	CbGeAlD
Vidarabine—ADK—endocrine gland—breast cancer	0.00141	0.0239	CbGeAlD
Vidarabine—DPP4—endocrine gland—breast cancer	0.00136	0.0231	CbGeAlD
Vidarabine—ADA—lymph node—breast cancer	0.00119	0.0202	CbGeAlD
Vidarabine—ADK—lymph node—breast cancer	0.000973	0.0165	CbGeAlD
Vidarabine—DPP4—lymph node—breast cancer	0.000943	0.016	CbGeAlD
Vidarabine—Azacitidine—DNMT3A—breast cancer	0.000934	0.0927	CrCbGaD
Vidarabine—Decitabine—DNMT3A—breast cancer	0.000912	0.0905	CrCbGaD
Vidarabine—Adenosine triphosphate—ARAF—breast cancer	0.000854	0.0848	CrCbGaD
Vidarabine—Azacitidine—CDA—breast cancer	0.000833	0.0827	CrCbGaD
Vidarabine—Tenofovir—NME1—breast cancer	0.000773	0.0768	CrCbGaD
Vidarabine—Adenosine monophosphate—PIM1—breast cancer	0.000566	0.0562	CrCbGaD
Vidarabine—Azacitidine—DNMT1—breast cancer	0.000504	0.0501	CrCbGaD
Vidarabine—Decitabine—DNMT1—breast cancer	0.000492	0.0489	CrCbGaD
Vidarabine—Adenosine triphosphate—HSPA1B—breast cancer	0.000491	0.0487	CrCbGaD
Vidarabine—Adenosine monophosphate—APRT—breast cancer	0.000481	0.0478	CrCbGaD
Vidarabine—Cytarabine—CDA—breast cancer	0.000475	0.0472	CrCbGaD
Vidarabine—Glucosamine—IFNG—breast cancer	0.000429	0.0426	CrCbGaD
Vidarabine—Adenosine triphosphate—ACVR1—breast cancer	0.000417	0.0414	CrCbGaD
Vidarabine—Glucosamine—MMP9—breast cancer	0.000273	0.0271	CrCbGaD
Vidarabine—Adenosine triphosphate—ALK—breast cancer	0.000225	0.0224	CrCbGaD
Vidarabine—S-Adenosylmethionine—COMT—breast cancer	0.000204	0.0202	CrCbGaD
Vidarabine—Adenosine monophosphate—PDE4D—breast cancer	0.000198	0.0197	CrCbGaD
Vidarabine—Glucosamine—TNF—breast cancer	0.00018	0.0178	CrCbGaD
Vidarabine—Adenosine triphosphate—AKT1—breast cancer	0.000176	0.0175	CrCbGaD
Vidarabine—Adenosine monophosphate—SRC—breast cancer	0.000173	0.0172	CrCbGaD
Vidarabine—Adenosine triphosphate—ABL1—breast cancer	0.000166	0.0165	CrCbGaD
Vidarabine—Clofarabine—ABCG2—breast cancer	0.000151	0.015	CrCbGaD
Vidarabine—Anxiety—Paclitaxel—breast cancer	0.00012	0.000553	CcSEcCtD
Vidarabine—Nausea—Tamoxifen—breast cancer	0.000119	0.000549	CcSEcCtD
Vidarabine—Arrhythmia—Capecitabine—breast cancer	0.000119	0.000549	CcSEcCtD
Vidarabine—Discomfort—Paclitaxel—breast cancer	0.000119	0.000548	CcSEcCtD
Vidarabine—Abdominal discomfort—Methotrexate—breast cancer	0.000119	0.000548	CcSEcCtD
Vidarabine—Cardiac arrest—Doxorubicin—breast cancer	0.000118	0.000544	CcSEcCtD
Vidarabine—Pain—Gemcitabine—breast cancer	0.000118	0.000543	CcSEcCtD
Vidarabine—Dry mouth—Paclitaxel—breast cancer	0.000117	0.000543	CcSEcCtD
Vidarabine—Mood swings—Doxorubicin—breast cancer	0.000117	0.000542	CcSEcCtD
Vidarabine—Asthenia—Thiotepa—breast cancer	0.000117	0.000542	CcSEcCtD
Vidarabine—Dysgeusia—Docetaxel—breast cancer	0.000117	0.000541	CcSEcCtD
Vidarabine—Nausea—Melphalan—breast cancer	0.000116	0.000538	CcSEcCtD
Vidarabine—Back pain—Docetaxel—breast cancer	0.000116	0.000534	CcSEcCtD
Vidarabine—Pain—Fluorouracil—breast cancer	0.000116	0.000534	CcSEcCtD
Vidarabine—Anaphylactic shock—Paclitaxel—breast cancer	0.000115	0.000532	CcSEcCtD
Vidarabine—Nausea—Goserelin—breast cancer	0.000113	0.000524	CcSEcCtD
Vidarabine—Dysgeusia—Capecitabine—breast cancer	0.000113	0.000524	CcSEcCtD
Vidarabine—Shock—Paclitaxel—breast cancer	0.000113	0.000523	CcSEcCtD
Vidarabine—Dizziness—Vinorelbine—breast cancer	0.000113	0.000523	CcSEcCtD
Vidarabine—Tachycardia—Paclitaxel—breast cancer	0.000112	0.000519	CcSEcCtD
Vidarabine—Urticaria—Mitoxantrone—breast cancer	0.000112	0.000518	CcSEcCtD
Vidarabine—Back pain—Capecitabine—breast cancer	0.000112	0.000517	CcSEcCtD
Vidarabine—Hyperhidrosis—Paclitaxel—breast cancer	0.000111	0.000514	CcSEcCtD
Vidarabine—Drowsiness—Methotrexate—breast cancer	0.00011	0.000509	CcSEcCtD
Vidarabine—Vision blurred—Capecitabine—breast cancer	0.000109	0.000504	CcSEcCtD
Vidarabine—Vomiting—Vinorelbine—breast cancer	0.000109	0.000503	CcSEcCtD
Vidarabine—Tremor—Capecitabine—breast cancer	0.000108	0.000501	CcSEcCtD
Vidarabine—Dizziness—Thiotepa—breast cancer	0.000108	0.000499	CcSEcCtD
Vidarabine—Rash—Vinorelbine—breast cancer	0.000108	0.000499	CcSEcCtD
Vidarabine—Dermatitis—Vinorelbine—breast cancer	0.000108	0.000498	CcSEcCtD
Vidarabine—Hypotension—Paclitaxel—breast cancer	0.000108	0.000497	CcSEcCtD
Vidarabine—Urticaria—Fluorouracil—breast cancer	0.000107	0.000496	CcSEcCtD
Vidarabine—Headache—Vinorelbine—breast cancer	0.000107	0.000495	CcSEcCtD
Vidarabine—Syncope—Docetaxel—breast cancer	0.000107	0.000495	CcSEcCtD
Vidarabine—Pollakiuria—Epirubicin—breast cancer	0.000107	0.000494	CcSEcCtD
Vidarabine—Sweating—Methotrexate—breast cancer	0.000106	0.000488	CcSEcCtD
Vidarabine—Palpitations—Docetaxel—breast cancer	0.000106	0.000488	CcSEcCtD
Vidarabine—Loss of consciousness—Docetaxel—breast cancer	0.000105	0.000485	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Paclitaxel—breast cancer	0.000105	0.000485	CcSEcCtD
Vidarabine—Cough—Docetaxel—breast cancer	0.000104	0.000482	CcSEcCtD
Vidarabine—Hypersensitivity—Mitoxantrone—breast cancer	0.000104	0.00048	CcSEcCtD
Vidarabine—Hypersensitivity—Irinotecan—breast cancer	0.000104	0.00048	CcSEcCtD
Vidarabine—Vomiting—Thiotepa—breast cancer	0.000104	0.00048	CcSEcCtD
Vidarabine—Syncope—Capecitabine—breast cancer	0.000104	0.00048	CcSEcCtD
Vidarabine—Convulsion—Docetaxel—breast cancer	0.000104	0.000479	CcSEcCtD
Vidarabine—Paraesthesia—Paclitaxel—breast cancer	0.000103	0.000478	CcSEcCtD
Vidarabine—Hypertension—Docetaxel—breast cancer	0.000103	0.000477	CcSEcCtD
Vidarabine—Drowsiness—Epirubicin—breast cancer	0.000103	0.000477	CcSEcCtD
Vidarabine—Rash—Thiotepa—breast cancer	0.000103	0.000476	CcSEcCtD
Vidarabine—Dermatitis—Thiotepa—breast cancer	0.000103	0.000476	CcSEcCtD
Vidarabine—Dyspnoea—Paclitaxel—breast cancer	0.000103	0.000474	CcSEcCtD
Vidarabine—Headache—Thiotepa—breast cancer	0.000102	0.000473	CcSEcCtD
Vidarabine—Somnolence—Paclitaxel—breast cancer	0.000102	0.000473	CcSEcCtD
Vidarabine—Palpitations—Capecitabine—breast cancer	0.000102	0.000473	CcSEcCtD
Vidarabine—Chest pain—Docetaxel—breast cancer	0.000102	0.00047	CcSEcCtD
Vidarabine—Loss of consciousness—Capecitabine—breast cancer	0.000102	0.00047	CcSEcCtD
Vidarabine—Nausea—Vinorelbine—breast cancer	0.000102	0.00047	CcSEcCtD
Vidarabine—Asthenia—Irinotecan—breast cancer	0.000101	0.000468	CcSEcCtD
Vidarabine—Asthenia—Mitoxantrone—breast cancer	0.000101	0.000468	CcSEcCtD
Vidarabine—Cough—Capecitabine—breast cancer	0.000101	0.000467	CcSEcCtD
Vidarabine—Hypertension—Capecitabine—breast cancer	9.99e-05	0.000462	CcSEcCtD
Vidarabine—Hypersensitivity—Fluorouracil—breast cancer	9.96e-05	0.00046	CcSEcCtD
Vidarabine—Dry mouth—Docetaxel—breast cancer	9.95e-05	0.00046	CcSEcCtD
Vidarabine—Sweating—Epirubicin—breast cancer	9.89e-05	0.000457	CcSEcCtD
Vidarabine—Pollakiuria—Doxorubicin—breast cancer	9.89e-05	0.000457	CcSEcCtD
Vidarabine—Asthenia—Gemcitabine—breast cancer	9.86e-05	0.000456	CcSEcCtD
Vidarabine—Chest pain—Capecitabine—breast cancer	9.85e-05	0.000455	CcSEcCtD
Vidarabine—Pain—Paclitaxel—breast cancer	9.84e-05	0.000455	CcSEcCtD
Vidarabine—Anxiety—Capecitabine—breast cancer	9.82e-05	0.000454	CcSEcCtD
Vidarabine—Anaphylactic shock—Docetaxel—breast cancer	9.76e-05	0.000451	CcSEcCtD
Vidarabine—Discomfort—Capecitabine—breast cancer	9.73e-05	0.00045	CcSEcCtD
Vidarabine—Nausea—Thiotepa—breast cancer	9.71e-05	0.000449	CcSEcCtD
Vidarabine—Dry mouth—Capecitabine—breast cancer	9.64e-05	0.000445	CcSEcCtD
Vidarabine—Shock—Docetaxel—breast cancer	9.6e-05	0.000444	CcSEcCtD
Vidarabine—Drowsiness—Doxorubicin—breast cancer	9.55e-05	0.000441	CcSEcCtD
Vidarabine—Tachycardia—Docetaxel—breast cancer	9.52e-05	0.00044	CcSEcCtD
Vidarabine—Bradycardia—Epirubicin—breast cancer	9.43e-05	0.000436	CcSEcCtD
Vidarabine—Dizziness—Irinotecan—breast cancer	9.33e-05	0.000431	CcSEcCtD
Vidarabine—Shock—Capecitabine—breast cancer	9.29e-05	0.000429	CcSEcCtD
Vidarabine—Tinnitus—Methotrexate—breast cancer	9.23e-05	0.000426	CcSEcCtD
Vidarabine—Tachycardia—Capecitabine—breast cancer	9.22e-05	0.000426	CcSEcCtD
Vidarabine—Hypoaesthesia—Epirubicin—breast cancer	9.21e-05	0.000426	CcSEcCtD
Vidarabine—Cardiac disorder—Methotrexate—breast cancer	9.18e-05	0.000424	CcSEcCtD
Vidarabine—Sweating—Doxorubicin—breast cancer	9.15e-05	0.000423	CcSEcCtD
Vidarabine—Urticaria—Paclitaxel—breast cancer	9.14e-05	0.000423	CcSEcCtD
Vidarabine—Hyperhidrosis—Capecitabine—breast cancer	9.13e-05	0.000422	CcSEcCtD
Vidarabine—Hypotension—Docetaxel—breast cancer	9.12e-05	0.000421	CcSEcCtD
Vidarabine—Vomiting—Mitoxantrone—breast cancer	8.97e-05	0.000415	CcSEcCtD
Vidarabine—Vomiting—Irinotecan—breast cancer	8.97e-05	0.000415	CcSEcCtD
Vidarabine—Dizziness—Fluorouracil—breast cancer	8.94e-05	0.000413	CcSEcCtD
Vidarabine—Mediastinal disorder—Methotrexate—breast cancer	8.92e-05	0.000412	CcSEcCtD
Vidarabine—Rash—Mitoxantrone—breast cancer	8.9e-05	0.000411	CcSEcCtD
Vidarabine—Rash—Irinotecan—breast cancer	8.9e-05	0.000411	CcSEcCtD
Vidarabine—Dermatitis—Irinotecan—breast cancer	8.89e-05	0.000411	CcSEcCtD
Vidarabine—Dermatitis—Mitoxantrone—breast cancer	8.89e-05	0.000411	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Docetaxel—breast cancer	8.89e-05	0.000411	CcSEcCtD
Vidarabine—Headache—Mitoxantrone—breast cancer	8.84e-05	0.000409	CcSEcCtD
Vidarabine—Headache—Irinotecan—breast cancer	8.84e-05	0.000409	CcSEcCtD
Vidarabine—Hypotension—Capecitabine—breast cancer	8.83e-05	0.000408	CcSEcCtD
Vidarabine—Paraesthesia—Docetaxel—breast cancer	8.76e-05	0.000405	CcSEcCtD
Vidarabine—Vomiting—Gemcitabine—breast cancer	8.74e-05	0.000404	CcSEcCtD
Vidarabine—Bradycardia—Doxorubicin—breast cancer	8.72e-05	0.000403	CcSEcCtD
Vidarabine—Dyspnoea—Docetaxel—breast cancer	8.7e-05	0.000402	CcSEcCtD
Vidarabine—Cladribine—ABCG2—breast cancer	8.68e-05	0.00862	CrCbGaD
Vidarabine—Somnolence—Docetaxel—breast cancer	8.67e-05	0.000401	CcSEcCtD
Vidarabine—Rash—Gemcitabine—breast cancer	8.67e-05	0.000401	CcSEcCtD
Vidarabine—Dermatitis—Gemcitabine—breast cancer	8.66e-05	0.0004	CcSEcCtD
Vidarabine—Tinnitus—Epirubicin—breast cancer	8.63e-05	0.000399	CcSEcCtD
Vidarabine—Headache—Gemcitabine—breast cancer	8.61e-05	0.000398	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Capecitabine—breast cancer	8.6e-05	0.000398	CcSEcCtD
Vidarabine—Cardiac disorder—Epirubicin—breast cancer	8.6e-05	0.000397	CcSEcCtD
Vidarabine—Flushing—Epirubicin—breast cancer	8.6e-05	0.000397	CcSEcCtD
Vidarabine—Vomiting—Fluorouracil—breast cancer	8.59e-05	0.000397	CcSEcCtD
Vidarabine—Hypoaesthesia—Doxorubicin—breast cancer	8.53e-05	0.000394	CcSEcCtD
Vidarabine—Rash—Fluorouracil—breast cancer	8.52e-05	0.000394	CcSEcCtD
Vidarabine—Dermatitis—Fluorouracil—breast cancer	8.51e-05	0.000393	CcSEcCtD
Vidarabine—Paraesthesia—Capecitabine—breast cancer	8.48e-05	0.000392	CcSEcCtD
Vidarabine—Hypersensitivity—Paclitaxel—breast cancer	8.48e-05	0.000392	CcSEcCtD
Vidarabine—Headache—Fluorouracil—breast cancer	8.47e-05	0.000391	CcSEcCtD
Vidarabine—Dysgeusia—Methotrexate—breast cancer	8.44e-05	0.00039	CcSEcCtD
Vidarabine—Dyspnoea—Capecitabine—breast cancer	8.42e-05	0.000389	CcSEcCtD
Vidarabine—Nausea—Irinotecan—breast cancer	8.38e-05	0.000387	CcSEcCtD
Vidarabine—Nausea—Mitoxantrone—breast cancer	8.38e-05	0.000387	CcSEcCtD
Vidarabine—Mediastinal disorder—Epirubicin—breast cancer	8.35e-05	0.000386	CcSEcCtD
Vidarabine—Pain—Docetaxel—breast cancer	8.34e-05	0.000385	CcSEcCtD
Vidarabine—Back pain—Methotrexate—breast cancer	8.33e-05	0.000385	CcSEcCtD
Vidarabine—Arrhythmia—Epirubicin—breast cancer	8.27e-05	0.000382	CcSEcCtD
Vidarabine—Asthenia—Paclitaxel—breast cancer	8.26e-05	0.000382	CcSEcCtD
Vidarabine—Nausea—Gemcitabine—breast cancer	8.17e-05	0.000377	CcSEcCtD
Vidarabine—Vision blurred—Methotrexate—breast cancer	8.12e-05	0.000375	CcSEcCtD
Vidarabine—Pain—Capecitabine—breast cancer	8.08e-05	0.000373	CcSEcCtD
Vidarabine—Nausea—Fluorouracil—breast cancer	8.03e-05	0.000371	CcSEcCtD
Vidarabine—Tinnitus—Doxorubicin—breast cancer	7.99e-05	0.000369	CcSEcCtD
Vidarabine—Flushing—Doxorubicin—breast cancer	7.95e-05	0.000368	CcSEcCtD
Vidarabine—Cardiac disorder—Doxorubicin—breast cancer	7.95e-05	0.000368	CcSEcCtD
Vidarabine—Tension—Epirubicin—breast cancer	7.91e-05	0.000366	CcSEcCtD
Vidarabine—Dysgeusia—Epirubicin—breast cancer	7.89e-05	0.000365	CcSEcCtD
Vidarabine—Nervousness—Epirubicin—breast cancer	7.83e-05	0.000362	CcSEcCtD
Vidarabine—Back pain—Epirubicin—breast cancer	7.8e-05	0.00036	CcSEcCtD
Vidarabine—Mediastinal disorder—Doxorubicin—breast cancer	7.72e-05	0.000357	CcSEcCtD
Vidarabine—Arrhythmia—Doxorubicin—breast cancer	7.66e-05	0.000354	CcSEcCtD
Vidarabine—Dizziness—Paclitaxel—breast cancer	7.61e-05	0.000352	CcSEcCtD
Vidarabine—Vision blurred—Epirubicin—breast cancer	7.6e-05	0.000351	CcSEcCtD
Vidarabine—Cough—Methotrexate—breast cancer	7.52e-05	0.000347	CcSEcCtD
Vidarabine—Urticaria—Capecitabine—breast cancer	7.5e-05	0.000347	CcSEcCtD
Vidarabine—Convulsion—Methotrexate—breast cancer	7.46e-05	0.000345	CcSEcCtD
Vidarabine—Agitation—Epirubicin—breast cancer	7.41e-05	0.000342	CcSEcCtD
Vidarabine—Chest pain—Methotrexate—breast cancer	7.33e-05	0.000339	CcSEcCtD
Vidarabine—Tension—Doxorubicin—breast cancer	7.32e-05	0.000338	CcSEcCtD
Vidarabine—Vomiting—Paclitaxel—breast cancer	7.32e-05	0.000338	CcSEcCtD
Vidarabine—Dysgeusia—Doxorubicin—breast cancer	7.31e-05	0.000338	CcSEcCtD
Vidarabine—Rash—Paclitaxel—breast cancer	7.26e-05	0.000335	CcSEcCtD
Vidarabine—Dermatitis—Paclitaxel—breast cancer	7.25e-05	0.000335	CcSEcCtD
Vidarabine—Discomfort—Methotrexate—breast cancer	7.25e-05	0.000335	CcSEcCtD
Vidarabine—Nervousness—Doxorubicin—breast cancer	7.25e-05	0.000335	CcSEcCtD
Vidarabine—Syncope—Epirubicin—breast cancer	7.23e-05	0.000334	CcSEcCtD
Vidarabine—Back pain—Doxorubicin—breast cancer	7.22e-05	0.000333	CcSEcCtD
Vidarabine—Headache—Paclitaxel—breast cancer	7.21e-05	0.000333	CcSEcCtD
Vidarabine—Hypersensitivity—Docetaxel—breast cancer	7.19e-05	0.000332	CcSEcCtD
Vidarabine—Palpitations—Epirubicin—breast cancer	7.12e-05	0.000329	CcSEcCtD
Vidarabine—Loss of consciousness—Epirubicin—breast cancer	7.09e-05	0.000327	CcSEcCtD
Vidarabine—Cough—Epirubicin—breast cancer	7.04e-05	0.000325	CcSEcCtD
Vidarabine—Anaphylactic shock—Methotrexate—breast cancer	7.03e-05	0.000325	CcSEcCtD
Vidarabine—Vision blurred—Doxorubicin—breast cancer	7.03e-05	0.000325	CcSEcCtD
Vidarabine—Asthenia—Docetaxel—breast cancer	7e-05	0.000323	CcSEcCtD
Vidarabine—Convulsion—Epirubicin—breast cancer	6.99e-05	0.000323	CcSEcCtD
Vidarabine—Hypertension—Epirubicin—breast cancer	6.96e-05	0.000322	CcSEcCtD
Vidarabine—Hypersensitivity—Capecitabine—breast cancer	6.96e-05	0.000322	CcSEcCtD
Vidarabine—Chest pain—Epirubicin—breast cancer	6.86e-05	0.000317	CcSEcCtD
Vidarabine—Agitation—Doxorubicin—breast cancer	6.86e-05	0.000317	CcSEcCtD
Vidarabine—Anxiety—Epirubicin—breast cancer	6.84e-05	0.000316	CcSEcCtD
Vidarabine—Nausea—Paclitaxel—breast cancer	6.84e-05	0.000316	CcSEcCtD
Vidarabine—Hyperhidrosis—Methotrexate—breast cancer	6.8e-05	0.000314	CcSEcCtD
Vidarabine—Discomfort—Epirubicin—breast cancer	6.78e-05	0.000313	CcSEcCtD
Vidarabine—Asthenia—Capecitabine—breast cancer	6.78e-05	0.000313	CcSEcCtD
Vidarabine—Dry mouth—Epirubicin—breast cancer	6.71e-05	0.00031	CcSEcCtD
Vidarabine—Syncope—Doxorubicin—breast cancer	6.69e-05	0.000309	CcSEcCtD
Vidarabine—Palpitations—Doxorubicin—breast cancer	6.59e-05	0.000305	CcSEcCtD
Vidarabine—Anaphylactic shock—Epirubicin—breast cancer	6.58e-05	0.000304	CcSEcCtD
Vidarabine—Hypotension—Methotrexate—breast cancer	6.57e-05	0.000304	CcSEcCtD
Vidarabine—Loss of consciousness—Doxorubicin—breast cancer	6.56e-05	0.000303	CcSEcCtD
Vidarabine—Cough—Doxorubicin—breast cancer	6.51e-05	0.000301	CcSEcCtD
Vidarabine—Shock—Epirubicin—breast cancer	6.47e-05	0.000299	CcSEcCtD
Vidarabine—Convulsion—Doxorubicin—breast cancer	6.46e-05	0.000299	CcSEcCtD
Vidarabine—Dizziness—Docetaxel—breast cancer	6.45e-05	0.000298	CcSEcCtD
Vidarabine—Hypertension—Doxorubicin—breast cancer	6.44e-05	0.000298	CcSEcCtD
Vidarabine—Tachycardia—Epirubicin—breast cancer	6.42e-05	0.000297	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Methotrexate—breast cancer	6.41e-05	0.000296	CcSEcCtD
Vidarabine—Hyperhidrosis—Epirubicin—breast cancer	6.36e-05	0.000294	CcSEcCtD
Vidarabine—Chest pain—Doxorubicin—breast cancer	6.35e-05	0.000293	CcSEcCtD
Vidarabine—Anxiety—Doxorubicin—breast cancer	6.33e-05	0.000292	CcSEcCtD
Vidarabine—Paraesthesia—Methotrexate—breast cancer	6.31e-05	0.000292	CcSEcCtD
Vidarabine—Discomfort—Doxorubicin—breast cancer	6.27e-05	0.00029	CcSEcCtD
Vidarabine—Dyspnoea—Methotrexate—breast cancer	6.27e-05	0.00029	CcSEcCtD
Vidarabine—Somnolence—Methotrexate—breast cancer	6.25e-05	0.000289	CcSEcCtD
Vidarabine—Dizziness—Capecitabine—breast cancer	6.25e-05	0.000289	CcSEcCtD
Vidarabine—Dry mouth—Doxorubicin—breast cancer	6.21e-05	0.000287	CcSEcCtD
Vidarabine—Vomiting—Docetaxel—breast cancer	6.2e-05	0.000287	CcSEcCtD
Vidarabine—Rash—Docetaxel—breast cancer	6.15e-05	0.000284	CcSEcCtD
Vidarabine—Hypotension—Epirubicin—breast cancer	6.15e-05	0.000284	CcSEcCtD
Vidarabine—Dermatitis—Docetaxel—breast cancer	6.15e-05	0.000284	CcSEcCtD
Vidarabine—Headache—Docetaxel—breast cancer	6.11e-05	0.000282	CcSEcCtD
Vidarabine—Anaphylactic shock—Doxorubicin—breast cancer	6.09e-05	0.000281	CcSEcCtD
Vidarabine—Pain—Methotrexate—breast cancer	6.01e-05	0.000278	CcSEcCtD
Vidarabine—Vomiting—Capecitabine—breast cancer	6.01e-05	0.000278	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Epirubicin—breast cancer	5.99e-05	0.000277	CcSEcCtD
Vidarabine—Shock—Doxorubicin—breast cancer	5.99e-05	0.000277	CcSEcCtD
Vidarabine—Rash—Capecitabine—breast cancer	5.96e-05	0.000275	CcSEcCtD
Vidarabine—Dermatitis—Capecitabine—breast cancer	5.95e-05	0.000275	CcSEcCtD
Vidarabine—Tachycardia—Doxorubicin—breast cancer	5.94e-05	0.000275	CcSEcCtD
Vidarabine—Headache—Capecitabine—breast cancer	5.92e-05	0.000273	CcSEcCtD
Vidarabine—Paraesthesia—Epirubicin—breast cancer	5.91e-05	0.000273	CcSEcCtD
Vidarabine—Hyperhidrosis—Doxorubicin—breast cancer	5.89e-05	0.000272	CcSEcCtD
Vidarabine—Dyspnoea—Epirubicin—breast cancer	5.87e-05	0.000271	CcSEcCtD
Vidarabine—Somnolence—Epirubicin—breast cancer	5.85e-05	0.00027	CcSEcCtD
Vidarabine—Nausea—Docetaxel—breast cancer	5.79e-05	0.000268	CcSEcCtD
Vidarabine—Hypotension—Doxorubicin—breast cancer	5.69e-05	0.000263	CcSEcCtD
Vidarabine—Pain—Epirubicin—breast cancer	5.63e-05	0.00026	CcSEcCtD
Vidarabine—Nausea—Capecitabine—breast cancer	5.61e-05	0.000259	CcSEcCtD
Vidarabine—Urticaria—Methotrexate—breast cancer	5.59e-05	0.000258	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Doxorubicin—breast cancer	5.55e-05	0.000256	CcSEcCtD
Vidarabine—Paraesthesia—Doxorubicin—breast cancer	5.47e-05	0.000253	CcSEcCtD
Vidarabine—Dyspnoea—Doxorubicin—breast cancer	5.43e-05	0.000251	CcSEcCtD
Vidarabine—Somnolence—Doxorubicin—breast cancer	5.41e-05	0.00025	CcSEcCtD
Vidarabine—Urticaria—Epirubicin—breast cancer	5.23e-05	0.000242	CcSEcCtD
Vidarabine—Pain—Doxorubicin—breast cancer	5.21e-05	0.000241	CcSEcCtD
Vidarabine—Hypersensitivity—Methotrexate—breast cancer	5.18e-05	0.000239	CcSEcCtD
Vidarabine—Asthenia—Methotrexate—breast cancer	5.04e-05	0.000233	CcSEcCtD
Vidarabine—Hypersensitivity—Epirubicin—breast cancer	4.85e-05	0.000224	CcSEcCtD
Vidarabine—Urticaria—Doxorubicin—breast cancer	4.84e-05	0.000224	CcSEcCtD
Vidarabine—Asthenia—Epirubicin—breast cancer	4.72e-05	0.000218	CcSEcCtD
Vidarabine—Cytarabine—CYP3A4—breast cancer	4.71e-05	0.00468	CrCbGaD
Vidarabine—Dizziness—Methotrexate—breast cancer	4.65e-05	0.000215	CcSEcCtD
Vidarabine—Hypersensitivity—Doxorubicin—breast cancer	4.49e-05	0.000207	CcSEcCtD
Vidarabine—Vomiting—Methotrexate—breast cancer	4.47e-05	0.000207	CcSEcCtD
Vidarabine—Rash—Methotrexate—breast cancer	4.43e-05	0.000205	CcSEcCtD
Vidarabine—Dermatitis—Methotrexate—breast cancer	4.43e-05	0.000205	CcSEcCtD
Vidarabine—Headache—Methotrexate—breast cancer	4.4e-05	0.000204	CcSEcCtD
Vidarabine—Asthenia—Doxorubicin—breast cancer	4.37e-05	0.000202	CcSEcCtD
Vidarabine—ADA—Metabolism—SLC5A5—breast cancer	4.36e-05	0.000307	CbGpPWpGaD
Vidarabine—Dizziness—Epirubicin—breast cancer	4.35e-05	0.000201	CcSEcCtD
Vidarabine—ADORA2A—Signaling Pathways—PDE2A—breast cancer	4.34e-05	0.000306	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CCL27—breast cancer	4.34e-05	0.000306	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—INHBB—breast cancer	4.34e-05	0.000306	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CXCL3—breast cancer	4.34e-05	0.000306	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—EDNRB—breast cancer	4.29e-05	0.000302	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—SRC—breast cancer	4.28e-05	0.000301	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—MDM2—breast cancer	4.22e-05	0.000297	CbGpPWpGaD
Vidarabine—ADA—Metabolism—SLC2A1—breast cancer	4.21e-05	0.000296	CbGpPWpGaD
Vidarabine—ADA—Metabolism—NQO1—breast cancer	4.21e-05	0.000296	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—RAF1—breast cancer	4.21e-05	0.000296	CbGpPWpGaD
Vidarabine—ADK—Metabolism—MTHFR—breast cancer	4.2e-05	0.000295	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—RELA—breast cancer	4.19e-05	0.000295	CbGpPWpGaD
Vidarabine—Vomiting—Epirubicin—breast cancer	4.18e-05	0.000193	CcSEcCtD
Vidarabine—Nausea—Methotrexate—breast cancer	4.18e-05	0.000193	CcSEcCtD
Vidarabine—ADORA2A—Signaling by NGF—ERBB2—breast cancer	4.16e-05	0.000293	CbGpPWpGaD
Vidarabine—Rash—Epirubicin—breast cancer	4.15e-05	0.000192	CcSEcCtD
Vidarabine—Dermatitis—Epirubicin—breast cancer	4.14e-05	0.000192	CcSEcCtD
Vidarabine—ADORA2A—Signaling Pathways—DLL4—breast cancer	4.14e-05	0.000291	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—BMPR2—breast cancer	4.14e-05	0.000291	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—STAT3—breast cancer	4.13e-05	0.00029	CbGpPWpGaD
Vidarabine—Headache—Epirubicin—breast cancer	4.12e-05	0.00019	CcSEcCtD
Vidarabine—ADA—Metabolism—CYP3A4—breast cancer	4.11e-05	0.000289	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—CXCL8—breast cancer	4.11e-05	0.000289	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—PIK3CB—breast cancer	4.11e-05	0.000289	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—MTOR—breast cancer	4.11e-05	0.000289	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—CXCL2—breast cancer	4.07e-05	0.000287	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—AGTR2—breast cancer	4.07e-05	0.000287	CbGpPWpGaD
Vidarabine—ADA—Metabolism—CYP1B1—breast cancer	4.04e-05	0.000284	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—PTHLH—breast cancer	4.03e-05	0.000283	CbGpPWpGaD
Vidarabine—Dizziness—Doxorubicin—breast cancer	4.03e-05	0.000186	CcSEcCtD
Vidarabine—ADORA2A—Signaling Pathways—CDH5—breast cancer	3.97e-05	0.000279	CbGpPWpGaD
Vidarabine—ADA—Metabolism—HSP90AA1—breast cancer	3.96e-05	0.000279	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—MAPK3—breast cancer	3.94e-05	0.000277	CbGpPWpGaD
Vidarabine—Nausea—Epirubicin—breast cancer	3.91e-05	0.000181	CcSEcCtD
Vidarabine—ADORA2A—GPCR downstream signaling—CALCA—breast cancer	3.9e-05	0.000275	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—EDNRB—breast cancer	3.9e-05	0.000274	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—SFRP2—breast cancer	3.89e-05	0.000274	CbGpPWpGaD
Vidarabine—ADK—Metabolism—CAV1—breast cancer	3.87e-05	0.000272	CbGpPWpGaD
Vidarabine—Vomiting—Doxorubicin—breast cancer	3.87e-05	0.000179	CcSEcCtD
Vidarabine—ADORA2A—Signaling by NGF—CDKN1B—breast cancer	3.85e-05	0.000271	CbGpPWpGaD
Vidarabine—ADA—Metabolism—NCOA1—breast cancer	3.85e-05	0.000271	CbGpPWpGaD
Vidarabine—Rash—Doxorubicin—breast cancer	3.84e-05	0.000177	CcSEcCtD
Vidarabine—Dermatitis—Doxorubicin—breast cancer	3.84e-05	0.000177	CcSEcCtD
Vidarabine—ADORA2A—Signaling Pathways—PRLR—breast cancer	3.82e-05	0.000269	CbGpPWpGaD
Vidarabine—Headache—Doxorubicin—breast cancer	3.81e-05	0.000176	CcSEcCtD
Vidarabine—ADORA2A—GPCR downstream signaling—CXCR4—breast cancer	3.81e-05	0.000268	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—CXCL12—breast cancer	3.81e-05	0.000268	CbGpPWpGaD
Vidarabine—ADA—Metabolism—CYP19A1—breast cancer	3.8e-05	0.000267	CbGpPWpGaD
Vidarabine—ADA—Metabolism—STK11—breast cancer	3.8e-05	0.000267	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—CTNNB1—breast cancer	3.79e-05	0.000267	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—CASP3—breast cancer	3.78e-05	0.000266	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—EGFR—breast cancer	3.75e-05	0.000264	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—GLI2—breast cancer	3.69e-05	0.00026	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—VCP—breast cancer	3.69e-05	0.00026	CbGpPWpGaD
Vidarabine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—breast cancer	3.67e-05	0.000258	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—LEPR—breast cancer	3.63e-05	0.000256	CbGpPWpGaD
Vidarabine—Nausea—Doxorubicin—breast cancer	3.62e-05	0.000167	CcSEcCtD
Vidarabine—ADORA2A—Signaling by NGF—CDKN1A—breast cancer	3.56e-05	0.00025	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—PTEN—breast cancer	3.55e-05	0.00025	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—CALCA—breast cancer	3.55e-05	0.000249	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—KRAS—breast cancer	3.54e-05	0.000249	CbGpPWpGaD
Vidarabine—ADA—Metabolism—COMT—breast cancer	3.53e-05	0.000248	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PIK3CG—breast cancer	3.53e-05	0.000248	CbGpPWpGaD
Vidarabine—ADA—Metabolism—GSTP1—breast cancer	3.51e-05	0.000247	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—MAPK8—breast cancer	3.47e-05	0.000244	CbGpPWpGaD
Vidarabine—ADA—Metabolism—HMOX1—breast cancer	3.46e-05	0.000244	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—CXCL12—breast cancer	3.46e-05	0.000244	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—CXCR4—breast cancer	3.46e-05	0.000244	CbGpPWpGaD
Vidarabine—ADA—Metabolism—ITPR1—breast cancer	3.46e-05	0.000243	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—AGTR1—breast cancer	3.45e-05	0.000243	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—ARHGDIA—breast cancer	3.38e-05	0.000238	CbGpPWpGaD
Vidarabine—ADA—Metabolism—ABCB1—breast cancer	3.33e-05	0.000234	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—SRC—breast cancer	3.29e-05	0.000232	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—FST—breast cancer	3.29e-05	0.000232	CbGpPWpGaD
Vidarabine—ADA—Metabolism—TYMS—breast cancer	3.27e-05	0.00023	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—PIK3CA—breast cancer	3.25e-05	0.000229	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—HEY2—breast cancer	3.25e-05	0.000229	CbGpPWpGaD
Vidarabine—ADA—Metabolism—NCOR1—breast cancer	3.23e-05	0.000227	CbGpPWpGaD
Vidarabine—ADA—Metabolism—GSTM1—breast cancer	3.23e-05	0.000227	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PLA2G4A—breast cancer	3.23e-05	0.000227	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—RPS6KB2—breast cancer	3.21e-05	0.000226	CbGpPWpGaD
Vidarabine—ADORA2A—Circadian rythm related genes—TP53—breast cancer	3.21e-05	0.000226	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—RGS2—breast cancer	3.17e-05	0.000223	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—STAT3—breast cancer	3.17e-05	0.000223	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CCL20—breast cancer	3.14e-05	0.000221	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—AGTR1—breast cancer	3.13e-05	0.00022	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PIK3CD—breast cancer	3.1e-05	0.000218	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—ITPR1—breast cancer	3.09e-05	0.000218	CbGpPWpGaD
Vidarabine—ADA—Metabolism—GPX1—breast cancer	3.09e-05	0.000218	CbGpPWpGaD
Vidarabine—Adenosine triphosphate—ABCB1—breast cancer	3.07e-05	0.00305	CrCbGaD
Vidarabine—ADA—Metabolism—CYP1A1—breast cancer	3.06e-05	0.000215	CbGpPWpGaD
Vidarabine—ADK—Metabolism—ALB—breast cancer	3.06e-05	0.000215	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—TLE3—breast cancer	3.04e-05	0.000214	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—LPAR1—breast cancer	3.04e-05	0.000214	CbGpPWpGaD
Vidarabine—ADA—Metabolism—ERCC2—breast cancer	3.03e-05	0.000214	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—MAPK3—breast cancer	3.03e-05	0.000213	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—HRAS—breast cancer	3.01e-05	0.000212	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—HEY1—breast cancer	3.01e-05	0.000212	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—DLL1—breast cancer	2.95e-05	0.000208	CbGpPWpGaD
Vidarabine—ADORA2A—Circadian rythm related genes—IL6—breast cancer	2.94e-05	0.000207	CbGpPWpGaD
Vidarabine—ADK—Metabolism—NOS3—breast cancer	2.93e-05	0.000206	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—HIST1H2BK—breast cancer	2.9e-05	0.000204	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—HIST1H2BC—breast cancer	2.9e-05	0.000204	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—EGFR—breast cancer	2.88e-05	0.000203	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—IL6—breast cancer	2.88e-05	0.000203	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—GRB7—breast cancer	2.87e-05	0.000202	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PDE4D—breast cancer	2.87e-05	0.000202	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—CSF2—breast cancer	2.86e-05	0.000201	CbGpPWpGaD
Vidarabine—ADA—Metabolism—MTHFR—breast cancer	2.85e-05	0.000201	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—TAB2—breast cancer	2.82e-05	0.000199	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—ITPR1—breast cancer	2.81e-05	0.000198	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CNR2—breast cancer	2.8e-05	0.000197	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR ligand binding—CXCL8—breast cancer	2.8e-05	0.000197	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—MMP3—breast cancer	2.79e-05	0.000196	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—DKK1—breast cancer	2.73e-05	0.000192	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—KRAS—breast cancer	2.72e-05	0.000192	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—VEGFC—breast cancer	2.71e-05	0.000191	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PIK3CB—breast cancer	2.7e-05	0.00019	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PTGS2—breast cancer	2.68e-05	0.000188	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—JAG2—breast cancer	2.67e-05	0.000188	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—AKT1—breast cancer	2.66e-05	0.000187	CbGpPWpGaD
Vidarabine—ADA—Metabolism—CAV1—breast cancer	2.63e-05	0.000185	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—WNT1—breast cancer	2.63e-05	0.000185	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—PLA2G4A—breast cancer	2.62e-05	0.000185	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—CSF2—breast cancer	2.59e-05	0.000183	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—PIK3CA—breast cancer	2.5e-05	0.000176	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—NOTCH4—breast cancer	2.49e-05	0.000175	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—GZMB—breast cancer	2.48e-05	0.000174	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—AGTR2—breast cancer	2.41e-05	0.000169	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CXCL2—breast cancer	2.41e-05	0.000169	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PIK3CG—breast cancer	2.4e-05	0.000169	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PTHLH—breast cancer	2.38e-05	0.000167	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—BMP2—breast cancer	2.38e-05	0.000167	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PTEN—breast cancer	2.33e-05	0.000164	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—HRAS—breast cancer	2.32e-05	0.000163	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—EDNRB—breast cancer	2.3e-05	0.000162	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PGR—breast cancer	2.28e-05	0.000161	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—THBS1—breast cancer	2.27e-05	0.00016	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—IL6—breast cancer	2.22e-05	0.000156	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—FLT1—breast cancer	2.17e-05	0.000152	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—SQSTM1—breast cancer	2.16e-05	0.000152	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—FGF3—breast cancer	2.16e-05	0.000152	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—PIK3CG—breast cancer	2.15e-05	0.000151	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—JAG1—breast cancer	2.13e-05	0.00015	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PARP1—breast cancer	2.12e-05	0.000149	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—NOTCH3—breast cancer	2.12e-05	0.000149	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PIK3CD—breast cancer	2.11e-05	0.000148	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CALCA—breast cancer	2.09e-05	0.000147	CbGpPWpGaD
Vidarabine—ADA—Metabolism—ALB—breast cancer	2.08e-05	0.000146	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—RPS6—breast cancer	2.07e-05	0.000146	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—FGF4—breast cancer	2.05e-05	0.000145	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CXCR4—breast cancer	2.05e-05	0.000144	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CXCL12—breast cancer	2.05e-05	0.000144	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—AKT1—breast cancer	2.05e-05	0.000144	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PAK1—breast cancer	2.01e-05	0.000141	CbGpPWpGaD
Vidarabine—ADA—Metabolism—NOS3—breast cancer	1.99e-05	0.00014	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—TCF7L2—breast cancer	1.97e-05	0.000139	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—AKT2—breast cancer	1.96e-05	0.000138	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—PIK3CG—breast cancer	1.95e-05	0.000137	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—NOTCH2—breast cancer	1.9e-05	0.000134	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—HSP90AA1—breast cancer	1.9e-05	0.000134	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—PIK3CD—breast cancer	1.89e-05	0.000133	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—AGTR1—breast cancer	1.85e-05	0.00013	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PRL—breast cancer	1.85e-05	0.00013	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PIK3CB—breast cancer	1.84e-05	0.000129	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—STK11—breast cancer	1.82e-05	0.000128	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—ADAM10—breast cancer	1.82e-05	0.000128	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PTGS2—breast cancer	1.82e-05	0.000128	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PLG—breast cancer	1.8e-05	0.000127	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—AKT2—breast cancer	1.78e-05	0.000125	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—FGF10—breast cancer	1.77e-05	0.000125	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—PIK3CD—breast cancer	1.71e-05	0.000121	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PDGFA—breast cancer	1.71e-05	0.00012	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—TGFBR2—breast cancer	1.69e-05	0.000119	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—ITPR1—breast cancer	1.66e-05	0.000117	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—STAT5A—breast cancer	1.65e-05	0.000116	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—ERBB4—breast cancer	1.65e-05	0.000116	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—MMP3—breast cancer	1.65e-05	0.000116	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PIK3CA—breast cancer	1.65e-05	0.000116	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—PIK3CB—breast cancer	1.64e-05	0.000116	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—SMAD4—breast cancer	1.6e-05	0.000112	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—IGF1R—breast cancer	1.59e-05	0.000112	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PTEN—breast cancer	1.59e-05	0.000112	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—CXCL8—breast cancer	1.58e-05	0.000111	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—HES1—breast cancer	1.56e-05	0.00011	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—NCOR1—breast cancer	1.55e-05	0.000109	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PLA2G4A—breast cancer	1.55e-05	0.000109	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CSF2—breast cancer	1.53e-05	0.000108	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—FGF1—breast cancer	1.53e-05	0.000108	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—RAF1—breast cancer	1.53e-05	0.000108	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—NRG1—breast cancer	1.52e-05	0.000107	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—H2AFX—breast cancer	1.51e-05	0.000106	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—IL2—breast cancer	1.51e-05	0.000106	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—E2F1—breast cancer	1.5e-05	0.000106	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—PIK3CB—breast cancer	1.49e-05	0.000105	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—SPP1—breast cancer	1.44e-05	0.000101	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—CXCL8—breast cancer	1.43e-05	0.000101	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—ERBB3—breast cancer	1.43e-05	0.0001	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—FGFR2—breast cancer	1.42e-05	0.0001	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—IL2—breast cancer	1.37e-05	9.65e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—TERT—breast cancer	1.37e-05	9.62e-05	CbGpPWpGaD
Vidarabine—ADK—Metabolism—AKT1—breast cancer	1.35e-05	9.47e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—FGFR1—breast cancer	1.33e-05	9.34e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—HIF1A—breast cancer	1.31e-05	9.2e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—LEP—breast cancer	1.28e-05	8.98e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CAV1—breast cancer	1.26e-05	8.89e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—KDR—breast cancer	1.25e-05	8.79e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—ESR1—breast cancer	1.22e-05	8.57e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—FN1—breast cancer	1.2e-05	8.47e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—NFKBIA—breast cancer	1.19e-05	8.36e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—NOTCH1—breast cancer	1.18e-05	8.28e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—APC—breast cancer	1.15e-05	8.1e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PIK3CG—breast cancer	1.15e-05	8.1e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—KIT—breast cancer	1.15e-05	8.1e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—EGF—breast cancer	1.14e-05	8.01e-05	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PIK3CA—breast cancer	1.12e-05	7.88e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—MAPK3—breast cancer	1.1e-05	7.76e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—BRAF—breast cancer	1.08e-05	7.61e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—IGF1—breast cancer	1.05e-05	7.42e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—AKT2—breast cancer	1.05e-05	7.41e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—EGFR—breast cancer	1.05e-05	7.38e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PIK3CD—breast cancer	1.01e-05	7.12e-05	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—PIK3CA—breast cancer	1e-05	7.05e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—SERPINE1—breast cancer	1e-05	7.04e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—KRAS—breast cancer	9.91e-06	6.97e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—NOS3—breast cancer	9.56e-06	6.72e-05	CbGpPWpGaD
Vidarabine—ADA—Metabolism—AKT1—breast cancer	9.15e-06	6.44e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—PIK3CA—breast cancer	9.1e-06	6.41e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—MDM2—breast cancer	9.07e-06	6.38e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—RAF1—breast cancer	9.03e-06	6.36e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—RELA—breast cancer	8.99e-06	6.33e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—ERBB2—breast cancer	8.94e-06	6.29e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—MTOR—breast cancer	8.82e-06	6.21e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PIK3CB—breast cancer	8.82e-06	6.21e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CXCL8—breast cancer	8.48e-06	5.97e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—HRAS—breast cancer	8.42e-06	5.93e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CDKN1B—breast cancer	8.28e-06	5.83e-05	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—AKT1—breast cancer	8.19e-06	5.76e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CASP3—breast cancer	8.11e-06	5.71e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—IL2—breast cancer	8.1e-06	5.7e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—IL6—breast cancer	8.06e-06	5.67e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CCND1—breast cancer	7.9e-06	5.56e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—JUN—breast cancer	7.88e-06	5.55e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CTNNB1—breast cancer	7.82e-06	5.5e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—MMP9—breast cancer	7.67e-06	5.4e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CDKN1A—breast cancer	7.64e-06	5.38e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PTEN—breast cancer	7.62e-06	5.36e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—MAPK8—breast cancer	7.46e-06	5.25e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—AKT1—breast cancer	7.44e-06	5.23e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—SRC—breast cancer	7.07e-06	4.97e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—VEGFA—breast cancer	6.88e-06	4.84e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—STAT3—breast cancer	6.82e-06	4.8e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—MAPK3—breast cancer	6.51e-06	4.58e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—MYC—breast cancer	6.33e-06	4.46e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—TGFB1—breast cancer	6.32e-06	4.45e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—EGFR—breast cancer	6.2e-06	4.36e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—KRAS—breast cancer	5.85e-06	4.12e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PIK3CA—breast cancer	5.38e-06	3.78e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—TP53—breast cancer	5.2e-06	3.66e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—HRAS—breast cancer	4.97e-06	3.5e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—IL6—breast cancer	4.76e-06	3.35e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—AKT1—breast cancer	4.39e-06	3.09e-05	CbGpPWpGaD
